Skip to main content
. 2020 Jul 9;14:1753466620937194. doi: 10.1177/1753466620937194

Table 1.

Study characteristics of the included studies.

Study Study duration (weeks) Number of patients Treatment comparison/dose (µg) Mean age
(years)
Male
(%)
Baseline FEV1
% predicted
COPD severity by lung function Exacerbation risk by lung function Exacerbation history in previous year Exacerbation risk by previous AE
Bateman et al.13 26 474 Indacaterol 110/glycopyrronium 50 64.0 76.4 55.7 Moderate (63.8%) Severe (36.1%) Low 0 (73.7%) 1 (19.5%) ⩾2 (6.8%) Low
473 Glycopyrronium 50 64.3 77.2 55.1
480 Tiotropium 18 63.5 75.0 55.1
Wedzicha et al.14 64 729 Indacaterol 110/glycopyrronium 50 63.1 76.0 37.0 Severe (79.2%)
Very severe (20.8%)
High 0 (1.5%) 1 (76.5%) ⩾2 (21.4%) High
740 Glycopyrronium 50 63.1 73.0 37.3
737 Tiotropium 18 63.6 75.0 37.4
Decramer et al.15 study 1 24 212 Umeclidinium 62.5/vilanterol 25 63.0 70.0 48.0 Moderate (48.0%)
Severe (41.2%)
Very severe (10.8%)
High 0 (51.2%) ⩾1 (48.8%) Low
208 Tiotropium 18 62.6 67.0 47.8
Decramer et al.15 study 2 24 217 Umeclidinium 62.5/vilanterol 25 65.0 65.0 47.7 Moderate (43.9%)
Severe (43.2%)
Very severe (12.8%)
High 0 (66.5%) ⩾1 (33.5%) Low
222 Umeclidinium 125 64.5 67.0 46.2
215 Tiotropium 18 65.2 71.0 47.4
Maleki-Yazdi et al.16 24 454 Umeclidinium 62.5/vilanterol 25 61.9 68.0 46.2 Moderate (41.4%)
Severe (45.6%)
Very severe (12.9%)
High N/A N/A
451 Tiotropium 18 62.7 67.0 46.5
Singh et al.17 24 385 Aclidinium 400/formoterol 12 62.7 67.8 54.6 Moderate (59.2%)
Severe (40.8%)
Low N/A N/A
385 Aclidinium 400 63.1 66.5 53.6
Buhl et al.12 52 1029 Tiotropium 5/olodaterol 5 63.8 71.2 49.3 Moderate (49.4%)
Severe (38.6%)
Very severe (12.0%)
High N/A N/A
1033 Tiotropium 5 63.9 73.1 49.7
Hanania et al.18 52 1035 Glycopyrrolate 18/formoterol 9.6 62.7 54.3 43.4 Very severe (10.2%) N/A 0 (83.3%)
1 (9.5%) ⩾2 (7.2%)
Low
888 Glycopyrrolate 18 62.8 55.9 42.6
450 Tiotropium 18 62.9 59.6 42.7
D’Urzo et al.19 52 335 Aclidinium 400/formoterol 12 64.2 50.1 53.2 Moderate (56.3%)
Severe (43.7%)
Low 0 (79.2%) ⩾1 (20.8%) Low
337 Aclidinium 400 64.4 55.8 53.0
Calverley et al.8 52 3939 Tiotropium 5/olodaterol 5 66.5 71.0 44.6 N/A N/A 1 (55.7%) ⩾2 (44.3%) High
3941 Tiotropium 5 66.3 72.0 44.5

AE, acute exacerbations; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in the first second.

HHS Vulnerability Disclosure